Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacokinetics of a hematoregulatory peptide (SK&F 107647) in healthy male volunteers and in patients with colorectal or pancreatic adenocarcinoma not amenable to standard therapy
Autore:
Zia-Amirhosseini, P; Harris, RZ; Cowley, HC; Valle, JW; Citerone, DR; Boppana, VK; Scarffe, H; Watson, P; Davis, CB;
Indirizzi:
SmithKline Beecham Pharmaceut, Dept Drug Metab, King Of Prussia, PA 19406 USA SmithKline Beecham Pharmaceut King Of Prussia PA USA 19406 , PA 19406 USA SmithKline Beecham Pharmaceut, Dept Pharmacokinet, King Of Prussia, PA 19406 USA SmithKline Beecham Pharmaceut King Of Prussia PA USA 19406 , PA 19406 USA SmithKline Beecham Pharmaceut, Clin Pharmacol Unit, Harlow CM19 5AD, Essex, England SmithKline Beecham Pharmaceut Harlow Essex England CM19 5AD ssex, England SmithKline Beecham Pharmaceut, Antiinfect Therapeut Unit, Harlow CM19 5AD,Essex, England SmithKline Beecham Pharmaceut Harlow Essex England CM19 5ADssex, England Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England Christie Hosp NHS Trust Manchester Lancs England M20 4BX , Lancs, England
Titolo Testata:
PHARMACEUTICAL RESEARCH
fascicolo: 4, volume: 17, anno: 2000,
pagine: 385 - 390
SICI:
0724-8741(200004)17:4<385:POAHP(>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
SK-AND-F-107647; CLEARANCE;
Keywords:
SK&F 107647; peptide; pharmacokinetics; hematoregulatory; adenocarcinoma; cytokines;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
11
Recensione:
Indirizzi per estratti:
Indirizzo: Zia-Amirhosseini, P SmithKline Beecham Pharmaceut, Dept Drug Metab, King Of Prussia, PA 19406 USA SmithKline Beecham Pharmaceut King Of Prussia PA USA 19406
Citazione:
P. Zia-Amirhosseini et al., "Pharmacokinetics of a hematoregulatory peptide (SK&F 107647) in healthy male volunteers and in patients with colorectal or pancreatic adenocarcinoma not amenable to standard therapy", PHARM RES, 17(4), 2000, pp. 385-390

Abstract

Purpose. To describe the pharmacokinetics of SK&F 107647, a synthetic hematoregulatory peptide, in healthy volunteers and in patients with adenocarcinoma. Methods. SK&F 107647 pharmacokinetics were evaluated in 2 dose-escalation studies. Volunteers received SK&F 107647 as single 15-minute iv infusion doses of 1, 10, 100, 500, and 1000 mu g/kg. Cancer patients received 7-hour iv infusions of 0.001, 0.01, 0.1 and 1 mu g/kg once daily for 10 days. Drug concentrations were quantified in plasma and urine of healthy volunteers and on days 1 and 10 in plasma of cancer patients receiving the two top dose levels. Results. In volunteers, mean clearance (CL) ranged from 76.7 to 101 ml/hour/kg; mean volume of distribution at steady-state (V-ss) ranged from 175 to268 ml/kg. Most of the administered dose was renally excreted as intact peptide within 24 hours postinfusion. In patients, mean CL was 57.6 ml/hourkg, mean V-ss ranged from 128 to 150 ml/kg and terminal half-life from 2.1 to3.4 hours. There was little accumulation of drug. In both studies, linear pharmacokinetics was observed. Clearance approached normal glomerular Filtration rate (GFR) in volunteers and correlated with creatinine clearance in cancer patients. Conclusions. SK&F 107647 exhibits linear pharmacokinetics, a small V-ss, and clearance, primarily renal, approaching normal GFR.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 09:03:29